Urica Therapeutics is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of pharmaceutical products to treat gout and chronic kidney disease. Urica acquired the rights to develop and commercialize dotinurad, a potentially best-in-class URAT1 inhibitor, in the United States, United Kingdom, European Union and Canada from Fuji Yakuhin. Dotinurad has been approved to treat gout and hyperuricemia in Japan and is currently in a Phase 1 clinical trial in the United States. Urica was founded by Fortress Biotech, Inc. (NASDAQ: FBIO).
View our Corporate Presentation
View our Press Releases